#72
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians should counsel patients that recreational cannabis use is associated with increased stroke risk, requiring risk stratification and documented conversations about this cardiovascular hazard, particularly for patients with existing cerebrovascular disease or stroke risk factors. Patients who use cannabis need informed consent discussions about stroke mechanisms and should be monitored for neurological symptoms, while providers must consider cannabis use history when evaluating acute stroke presentations. This evidence strengthens clinical guidelines recommending cannabis avoidance in high-risk populations and supports screening for cannabis use as part of comprehensive stroke prevention strategies.
A recent meta-analysis has identified cannabis use as an independent risk factor for acute ischemic stroke, alongside other recreational drugs such as cocaine. The analysis synthesized evidence from multiple studies to quantify the association between cannabis consumption and stroke incidence, finding a statistically significant elevation in stroke risk among users compared to non-users. The mechanisms underlying this increased risk likely involve cannabis-induced alterations in blood pressure, heart rate, and prothrombotic effects, though the precise pathophysiology requires further investigation. Clinicians should be aware of this association when taking substance use histories from patients presenting with acute neurological symptoms or assessing stroke risk in their patient populations. Additionally, patients with personal or family history of stroke may benefit from counseling about the cardiovascular risks of cannabis use, particularly given increasing normalization and accessibility of the drug. Screening for cannabis use during cardiovascular risk assessment and providing evidence-based counseling about stroke risk should become part of routine clinical practice, especially in regions where cannabis is now legally available.
“What this data tells us is that we need to stratify cannabis users the way we do with alcohol or tobacco: occasional use carries a different risk profile than regular use, and smoked delivery carries different cerebrovascular risks than other routes, so our clinical counseling has to be specific rather than categorical.”
? While this meta-analysis adds to growing evidence linking cannabis use with increased stroke risk, clinicians should recognize that the magnitude of risk, dose-response relationships, and mechanisms remain incompletely characterized, and confounding factors such as concurrent tobacco use, route of administration, and frequency of use are often inadequately controlled in observational studies. The stroke risk appears to be real but relatively modest in absolute terms for most users, yet certain populations—including younger patients with fewer traditional cardiovascular risk factors and those using high-potency products—may face disproportionate vulnerability. Given the rising prevalence of cannabis use in many jurisdictions and evolving legalization, clinicians should routinely assess cannabis consumption patterns during cardiovascular risk stratification and stroke prevention discussions, particularly in younger patients presenting with unexplained cerebrovascular events. Until more granular evidence emerges on specific cannabis products and consumption methods, a practical approach is to counsel patients about this potential risk alongside other
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
